Rainbow Child. (RAINBOW)

FairStock Score: 56/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• ROE of 17.55% and ROCE of 18.69% indicate efficient capital use with a debt/equity of just 0.54.
• Piotroski F-Score of 8/9 and Altman Z-Score of 5.05 suggest strong financial health and low near-term bankruptcy risk.
• Positive free cash flow of ₹128 Cr and latest quarter net profit of ₹74 Cr show earnings are backed by cash generation.
• Five-year revenue CAGR of 18.46% shows proven growth in a specialized hospital niche, with promoter holding of 49.84% aligning interests.

Concerns

• Extreme valuation: P/E of 46.90, P/B of 8.78 and EV/EBITDA of 131.33 leave no margin for error.
• Growth deceleration: current sales growth is only 8.50% and profit growth 8.22%, well below the 18.46% five-year revenue CAGR.
• No margin of safety: price is far above Graham Number of ₹289.75 and DCF intrinsic value of ₹172.27, implying a margin of safety of -310.60%.
• Dividend yield of 0.25% is negligible, so returns depend entirely on future price appreciation or multiple expansion.

AI Analysis

I start with Benjamin Graham's first rule: an investment should have a margin of safety. Rainbow Children's is a solid hospital business, but the price of ₹1269.15 offers no margin at all. The company has good profitability -- ROE 17.55%, ROCE 18.69% -- and the balance sheet is not dangerous, with debt/equity 0.54 and an Altman Z-Score of 5.05. The Piotroski F-Score of 8/9 tells me the recent financial health is genuine, and free cash flow of ₹128 Cr supports the earnings reported. Promoters own 49.84%, so their interests are broadly aligned with ours. The historical growth is respectable: five-year revenue CAGR of 18.46%. But the latest quarter shows sales of ₹445 Cr and net profit of ₹74 Cr, and the current growth rates have slowed to 8.50% for sales and 8.22% for profit. A fast grower cannot be valued as if it will grow fast forever when the engine is decelerating. Graham would look at book value of ₹144.57 and say paying 8.78 times book is speculative. The Graham Number works out to ₹289.75, while the DCF value is only ₹172.27. At ₹1269.15, the margin of safety is deeply negative, around -310%. P/E of 46.90 and EV/EBITDA of 131.33 leave no room for error. Dividend yield of 0.25% means you are not being paid to wait. This is a good business, but a bad price. In the hospital sector, quality matters, and Rainbow may deserve a premium. But a premium of this size requires flawless execution and many years of 18% growth. The latest numbers suggest momentum has cooled. As Buffett likes to say, it is far better to buy a wonderful business at a fair price, but here we are being asked to pay an extraordinary price. I would wait for a better price or a clear reacceleration in growth before committing money.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer